경구 고형 제제 수탁제조 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 작용기서별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Oral Solid Dosage Contract Manufacturing Market Summary

The global oral solid dosage contract manufacturing market size was valued at USD 10.20 billion in 2025 and is projected to reach USD 21.25 billion by 2033, growing at a CAGR of 9.2% from 2026 to 2033. The market is experiencing growth driven by rising demand for outsourcing by pharmaceutical companies, expansion of generic drug market and patent expirations, continuous advancements in drug delivery technologies and increasing focus on supply chain resilience and localization.

Pharmaceutical and biopharmaceutical companies are outsourcing oral solid dosage (OSD) manufacturing to contract development and manufacturing organizations (CDMOs) in large numbers to reduce capital expenditure and operational complexity. In addition, developing in-house capabilities for formulation, scale-up, and commercial production requires significant investment in infrastructure, skilled labor, and regulatory compliance. By partnering with CDMOs, companies can focus on core competencies such as research, clinical development, and commercialization. For instance, in December 2025, Bora Pharmaceuticals and Corealis Pharma partnered to provide integrated oral solid dosage development and manufacturing services, combining early-stage expertise with commercial-scale capabilities to accelerate drug development and reduce outsourcing complexity. In addition, outsourcing also provides access to specialized technologies, flexible production capacity, and global regulatory expertise. This trend is particularly strong among small and mid-sized biotech firms that lack manufacturing capabilities, as well as large pharmaceutical companies seeking to optimize costs, enhance efficiency, and accelerate time-to-market for new drug products.

In addition, growing generic drug market, driven by patent expirations of blockbuster drugs, is boosting demand for OSD contract manufacturing. As patents expire, generic drug manufacturers aim to quickly develop and launch cost-effective alternatives to capture market share. This creates a need for rapid formulation development, scale-up, and high-volume production capabilities, which CDMOs are well-equipped to provide. In addition, increasing healthcare cost pressures and government initiatives to promote affordable medicines are accelerating generic drug adoption globally. CDMOs offer cost-efficient manufacturing solutions, regulatory support, and scalability, enabling generic companies to meet high demand while maintaining compliance and quality standards, thus fueling growth in the market.

Furthermore, continuous advancements in drug delivery technologies is one of the key driver OSD contract manufacturing market. According to a report of March 2026, increasing complexity of highly potent oral solid dosage (HPOSD) drugs accelerates the growing pipeline of potent, low-dosage, and specialized formulations that requires advanced containment systems, specialized facilities, and strict safety protocols. These manufacturing challenges, combined with evolving regulatory expectations and occupational safety requirements, make in-house production difficult for many pharmaceutical companies. As a result, companies are outsourcing to CDMOs in large numbers with high-containment infrastructure, technical expertise, and proven quality systems. In addition, the need for efficient tech transfer, scalability, and "right-first-time" manufacturing approaches is accelerating reliance on experienced partners.

Moreover, pharmaceutical companies are placing greater emphasis on building resilient and flexible supply chains, particularly after disruptions experienced during global crises. This has led to increased investment in regional manufacturing capabilities and partnerships with CDMOs to ensure consistent supply of oral solid dosage drugs. In addition, companies are adopting multi-site manufacturing strategies and nearshoring approaches to reduce dependency on single regions and mitigate risks related to logistics, geopolitics, and regulatory changes. CDMOs with global footprints and integrated service offerings are well-positioned to support these strategies. Their ability to provide comprehensive solutions, from development to commercial manufacturing across multiple regions, enhances supply chain agility and reliability, making them critical partners in the evolving pharmaceutical landscape.

Global Oral Solid Dosage Contract Manufacturing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global oral solid dosage contract manufacturing market based on product, mechanism, end use, and region.

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Tablets
• Capsules
• Powders
• Granules
• Others
• Mechanism Outlook (Revenue, USD Million, 2021 - 2033)
• Immediate Release
• Delayed Release
• Controlled Release
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Large Size Companies
• Medium & Small Size Companies
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Oman
  • Qatar

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Mechanism
  • 1.2.3. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Top-Down Analysis
  • 1.7.3. Bottom-Up Approach
  • 1.7.4. Multivariate Analysis
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Oral Solid Dosage Contract Manufacturing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Technological Advancements in Oral Solid Dosage (OSD) Forms
    • 3.2.1.2. Expansion of Manufacturing Capacity by CMOs & CDMOs for OSD
    • 3.2.1.4. Increasing Demand for One-Stop-Shop CMOs
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Strict Approval Criteria by Regulatory Authorities
    • 3.2.2.2. Lack of Experienced Technical Staff, Physical Capability, and Equipment Capacity
    • 3.2.2.3. Increasing Need for Biosimilars and Their Prominence in Addressing Cancer & Other Medical Conditions
• 3.3. Technology Landscape
  • 3.3.1. Manufacturing Technology
  • 3.3.2. Encapsulation Technology
  • 3.3.3. Coating Technology
  • 3.3.4. Packaging Technology
  • 3.3.5. Analytical Technology
• 3.4. Pricing Model Analysis
• 3.5. Tariff Impact Analysis
• 3.6. Value Chain Analysis
  • 3.6.1. Supply Trends
  • 3.6.2. Demand Trends
• 3.7. Market Analysis Tools
  • 3.7.1. Porter's Five Force Analysis
  • 3.7.2. PESTEL by SWOT Analysis

Chapter 4. Oral Solid Dosage Contract Manufacturing Market: Product Estimates & Trend Analysis

• 4.1. Oral Solid Dosage Contract Manufacturing Market, By Product: Segment Dashboard
• 4.2. Oral Solid Dosage Contract Manufacturing Market, By Product: Movement Analysis
• 4.3. Oral Solid Dosage Contract Manufacturing Market Estimates & Forecasts, By Product, 2021 - 2033
• 4.4. Tablets
  • 4.4.1. Tablets Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Capsules
  • 4.5.1. Capsules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Powders
  • 4.6.1. Powders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Granules
  • 4.7.1. Granules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.8. Others
  • 4.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Oral Solid Dosage Contract Manufacturing Market: Mechanism Estimates & Trend Analysis

• 5.1. Oral Solid Dosage Contract Manufacturing Market, By Mechanism: Segment Dashboard
• 5.2. Oral Solid Dosage Contract Manufacturing Market, By Mechanism: Movement Analysis
• 5.3. Oral Solid Dosage Contract Manufacturing Market Estimates & Forecasts, By Mechanism, 2021 - 2033
• 5.4. Immediate Release
  • 5.4.1. Immediate Release Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Delayed Release
  • 5.5.1. Delayed Release Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Controlled Release
  • 5.6.1. Controlled Release Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Oral Solid Dosage Contract Manufacturing Market: End Use Estimates & Trend Analysis

• 6.1. Oral Solid Dosage Contract Manufacturing Market, By End Use: Segment Dashboard
• 6.2. Oral Solid Dosage Contract Manufacturing Market, By End Use: Movement Analysis
• 6.3. Oral Solid Dosage Contract Manufacturing Market Estimates & Forecasts, By End Use, 2021 - 2033
• 6.4. Large Size Companies
  • 6.4.1. Large Size Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Medium & Small Size Companies
  • 6.5.1. Medium & Small Size Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Others
  • 6.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Oral Solid Dosage Contract Manufacturing Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Dashboard
• 7.2. Regional Market Share Analysis, 2025 & 2033
• 7.3. North America
  • 7.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.2. U.S
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Competitive Scenario
    • 7.3.2.3. Regulatory Framework
    • 7.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Competitive Scenario
    • 7.3.3.3. Regulatory Framework
    • 7.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Competitive Scenario
    • 7.3.4.3. Regulatory Framework
    • 7.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.2. UK
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. Germany
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Competitive Scenario
    • 7.4.5.3. Regulatory Framework
    • 7.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Competitive Scenario
    • 7.4.6.3. Regulatory Framework
    • 7.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.7. Denmark
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Competitive Scenario
    • 7.4.7.3. Regulatory Framework
    • 7.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.8. Sweden
    • 7.4.8.1. Key Country Dynamics
    • 7.4.8.2. Competitive Scenario
    • 7.4.8.3. Regulatory Framework
    • 7.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.9. Norway
    • 7.4.9.1. Key Country Dynamics
    • 7.4.9.2. Competitive Scenario
    • 7.4.9.3. Regulatory Framework
    • 7.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. Japan
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. China
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.5. Thailand
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.6. South Korea
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.7. Australia
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. MEA
  • 7.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. Saudi Arabia
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Competitive Scenario
    • 7.7.4.3. Regulatory Framework
    • 7.7.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Competitive Scenario
    • 7.7.5.3. Regulatory Framework
    • 7.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.6. Oman
    • 7.7.6.1. Key Country Dynamics
    • 7.7.6.2. Competitive Scenario
    • 7.7.6.3. Regulatory Framework
    • 7.7.6.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.7. Qatar
    • 7.7.7.1. Key Country Dynamics
    • 7.7.7.2. Competitive Scenario
    • 7.7.7.3. Regulatory Framework
    • 7.7.7.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Key Participant Categorization
  • 8.1.1. Market Leaders
  • 8.1.2. Emerging Players
• 8.2. Market Share/Assessment Analysis, 2025 (Heat Map Analysis)
• 8.3. Company Profiles
  • 8.3.1. Catalent Inc.
    • 8.3.1.1. Company Overview
    • 8.3.1.2. Financial Performance
    • 8.3.1.3. Service Benchmarking
    • 8.3.1.4. Strategic Initiatives
  • 8.3.2. Lonza
    • 8.3.2.1. Company Overview
    • 8.3.2.2. Financial Performance
    • 8.3.2.3. Service Benchmarking
    • 8.3.2.4. Strategic Initiatives
  • 8.3.3. Aenova Group
    • 8.3.3.1. Company Overview
    • 8.3.3.2. Financial Performance
    • 8.3.3.3. Service Benchmarking
    • 8.3.3.4. Strategic Initiatives
  • 8.3.4. Boehringer Ingelheim International GmbH
    • 8.3.4.1. Company Overview
    • 8.3.4.2. Financial Performance
    • 8.3.4.3. Service Benchmarking
    • 8.3.4.4. Strategic Initiatives
  • 8.3.5. Jubilant Pharmova Limited
    • 8.3.5.1. Company Overview
    • 8.3.5.2. Financial Performance
    • 8.3.5.3. Service Benchmarking
    • 8.3.5.4. Strategic Initiatives
  • 8.3.6. Patheon Pharma Services
    • 8.3.6.1. Company Overview
    • 8.3.6.2. Financial Performance
    • 8.3.6.3. Service Benchmarking
    • 8.3.6.4. Strategic Initiatives
  • 8.3.7. Recipharm AB.
    • 8.3.7.1. Company Overview
    • 8.3.7.2. Financial Performance
    • 8.3.7.3. Service Benchmarking
    • 8.3.7.4. Strategic Initiatives
  • 8.3.8. Corden Pharma International
    • 8.3.8.1. Company Overview
    • 8.3.8.2. Financial Performance
    • 8.3.8.3. Service Benchmarking
    • 8.3.8.4. Strategic Initiatives
  • 8.3.9. Siegfried Holding AG
    • 8.3.9.1. Company Overview
    • 8.3.9.2. Financial Performance
    • 8.3.9.3. Service Benchmarking
    • 8.3.9.4. Strategic Initiatives
  • 8.3.10. Piramal Pharma Solutions
    • 8.3.10.1. Company Overview
    • 8.3.10.2. Financial Performance
    • 8.3.10.3. Service Benchmarking
    • 8.3.10.4. Strategic Initiatives
  • 8.3.11. AbbVie Contract Manufacturing
    • 8.3.11.1. Company Overview
    • 8.3.11.2. Financial Performance
    • 8.3.11.3. Service Benchmarking
    • 8.3.11.4. Strategic Initiatives
  • 8.3.12. Next Pharma AB
    • 8.3.12.1. Company Overview
    • 8.3.12.2. Financial Performance
    • 8.3.12.3. Service Benchmarking
    • 8.3.12.4. Strategic Initiatives